CD22 is a B-cell surface protein and the docking site for the leukaemia ADC inotuzumab ozogamicin. This dossier gathers the 2 products (1 approved), 1 trial, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Siglec-2; inhibitory co-receptor of the B-cell receptor, rapidly internalising, which suits ADC delivery.
- B-ALL (>90%)
- B-cell lymphomas
- Hairy cell leukaemia
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Acute lymphoblastic leukaemia | >90% | expression on B-ALL blasts |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Products by modality and phase
Browse products →| Modality | Approved | Withdrawn or failed |
|---|---|---|
| ADC 1 | — | |
| Anti-CD22 immunotoxin 1 | — |
Trials
Evidence ranking →| Trial | Phase | Status | Setting | Result | Products |
|---|---|---|---|---|---|
| INO-VATE ALL NCT01564784 | 3 | Positive | Relapsed or refractory CD22+ B-ALL, adults: inotuzumab ozogamicin vs standard intensive chemotherapy | CR/CRi 80.7% vs 29.4%; OS 7.7 vs 6.7 months. |
Resistance routes that involve this target
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways where it is a node
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Ideas and companies
Key papers and the live literature
Preprints →- INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL · New England Journal of Medicine 2016
Query for this target: (TITLE:"CD22" OR ABSTRACT:"CD22") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD22, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd22.json. Licence CC BY 4.0.